Record ids. D-6-n is a Week 6 decision, J-n a journal entry, F-0n a review finding, DR6-n a data request, A-n an assumption; all are in the engagement record.
For: Sarah, for reference and answer. Prepared: 2026-10-23 by the consultancy's build team. Draft; not sent. Status of every question: open. Answer register: counsel-questions-csrd-pe-v1.csv. Each answer is recorded there with its date and source, and the applicability screen is updated from it.
We advise US mid-market private-equity managers on climate disclosure. The managers have US and EU investors. Some portfolio companies have EU subsidiaries or branches.
We need to know when, if ever, the EU Corporate Sustainability Reporting Directive (CSRD) reaches such a structure after the Omnibus I amendments. Our working reading is that it usually does not, because the turnover tests are not met. But six points decide the answer, and the text does not settle them.
That reading was made by our team and then tested by an independent AI desk review (not a lawyer). Both are summarised below for context only. Neither is legal advice. We are asking for yours.
Question. For Art 40a, which entity is the "ultimate parent undertaking" of a portfolio company's EU subsidiary: the fund (the LP vehicle), its GP, the manager, or a sponsor holding company above them? Does the control analysis of Art 22 apply by analogy to these non-EU vehicles under the law of the member state where the EU subsidiary sits?
Why it matters. Art 40a measures turnover "at the group level of that ultimate third-country parent undertaking". If the parent sits above the fund, the group could span several funds.
Our working assumption. The controlling fund is at least a parent, and plausibly the ultimate one. The term is undefined, so we cannot rule out a higher entity. (Our assumptions A-L1, A-L2 and A-L13.)
What your answer changes. Which entity's turnover is measured, and whether several funds are counted together.
Question. Where the ultimate parent prepares its accounts as an investment company (US GAAP ASC 946, or the IFRS 10 investment-entity exception) and does not consolidate portfolio companies, is "net turnover in the Union at its group level" (Art 40a(1)):
If (b), are sales between portfolio companies eliminated?
Why it matters. Under (a), the EUR 450m test is almost never met. Under (b), a portfolio with large EU sales could meet it. Art 2(5), as replaced by Directive (EU) 2022/2464, says net turnover for these undertakings is revenue "within the meaning of the financial reporting framework" of the undertaking, which points towards (a). "Group level" points towards (b).
Our working assumption. Undecided by the text (A-L3, A-L4, A-L12). For screening we use (b), because it is the cautious option.
What your answer changes. Whether the turnover test can be met at all for a buyout fund.
Question. On the facts above (operating partners, budget approval, management replacement, monitoring fees), does the fund meet the definition in Art 2(15)? The definition requires a sole object of acquiring, managing and profiting from holdings, "without involving themselves directly or indirectly in the management", without prejudice to shareholder rights. Recital 17 treats voting at general meetings, including on board appointments, as shareholder rights. Does the relevant national law add criteria?
Why it matters. Only a financial holding undertaking can use the Art 40a derogation, which lets EU subsidiaries and branches decide not to publish.
Our working assumption. A typical control buyout fund probably fails the "no involvement in management" condition. Board appointments by shareholder vote alone would not disqualify it. (A-L6.)
What your answer changes. Whether the derogation is available at all. Our screen counts it only on your written confirmation.
Question. The derogation requires the subsidiaries' "business models and operations" to be independent of one another. Recital 17 excludes subsidiaries that are closely interconnected, for example where one enables or directly supports another.
Why it matters. Many mid-market strategies are buy-and-build.
Our working assumption. The test applies to the group as a whole, with no company-by-company carve-out (A-L8, as corrected by the review).
What your answer changes. Whether a fund with even one buy-and-build platform can rely on the derogation.
Question. Member states must transpose Omnibus I by 19 March 2027, and Art 40a applies from financial years starting on or after 1 January 2028. For the member states where our clients' EU subsidiaries or branches are located:
Why it matters. The derogation is a choice the subsidiary or branch makes under national law, so the procedure and timing are national.
Our working assumption. Transposition follows the Directive's wording, and national details are unknown (A-L9).
What your answer changes. The timing and the steps a client must take.
Question. Where the manager also runs an EU parallel fund (for example a Luxembourg vehicle) that holds or co-holds portfolio companies:
Why it matters. An EU parent reports on its own account under Art 29a, not under Art 40a, with different thresholds.
Our working assumption. Art 29a applies if the vehicle is in scope and controls, and Art 29a(7a) is the relevant option (A-L11).
What your answer changes. Whether a manager with an EU fund has a direct EU reporting route.
A short answer per question is enough, with the provision or guidance relied on. We will:
counsel-questions-csrd-pe-v1.csv): answer, date, source, answered by;Portfolio edition: Kith Climate cohort case, fictional client.